Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Biond Biologics

Request full access

Innovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients

Misgav Am, IsraelFounded 2016Biotech & Life Sciences

About Biond Biologics

Biond Biologics is a biotechnology company focused on developing innovative therapies for novel oncology targets. The company operates in the biopharmaceutical market, aiming to uncover immunoregulatory pathways and enable the intracellular delivery of biologics. Biond Biologics serves clients in the pharmaceutical and healthcare sectors, including global pharma companies through collaborations and partnerships. The business model revolves around research and development (R&D) of proprietary technology platforms and novel therapeutic agents, such as BND-22, a macrophage activator currently in IND-enabling studies. The company generates revenue through strategic partnerships, licensing agreements, and financing rounds, including a completed Series B financing with participation from global biopharma companies. Biond Biologics has established a sustainable R&D hub in the Galilee, Israel, and continues to advance its pipeline of oncology therapies through rigorous proof-of-concept studies and clinical trials.

Source: Dealroom company data

At a glance

Status
Operational
Employees
35
Open positions
None listed
Dealroom signal
30.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Developer Tools, Biotechnology, Oncology, Autoimmune, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jun 2026 $8M $85M Guangzhou Industrial Investment Fund ↗
SERIES C✓Equity / VC Nov 2021 $15M $85M Heritage Group · Deep Insight · Harel Group —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Biond Biologics website traffic

Latest recorded traffic for Biond Biologics is 320 monthly website visits, up 255.6% over the last three months. Biond Biologics's team declined 2.8% over the past year.

Latest monthly visits320 3-month web change+255.6% 1-year team growth-2.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Biond Biologics in the Misgav Am ecosystem

Live from Dealroom

The Biond Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Israel Biotech Fund
  • Harel Group
  • SBI JI Innovation Fund
  • Celgene

Series B and later3 investors entered at this stage

  • Deep Insight
  • Heritage Group
  • Guangzhou Industrial Investment Fund

Other known investors1 additional known investor

  • GUTS Innovation
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Biond Biologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.